Generic Cytoxan is used for treating certain types of the following cancers: lymphoma, multiple myeloma, leukemia, mycosis fungoides, neuroblastoma, ovarian cancer, eye cancer and breast cancer. It is usually used in combination with other medicines. It may also be used to treat certain kidney problems (nephrotic syndrome) in children. More info »
Cyclophosphamide drug makes the bone marrow more tumor-friendly - News-Medical.net
Cyclophosphamide drug makes the bone marrow more tumor-friendlyNews-Medical.
Some doctors unaware of long-term side effects of cancer care - WANE
WANESome doctors unaware of long-term side effects of cancer careWANEIn the case of Cyclophosphamide, only 14% of primary care physicians knew women are likely to suffer premature menopause, compared to 71% of cancer specialists.
NCCN 17th Annual Conference: Clinical Practice Guidelines & Quality Cancer Care - OncLive
OncLiveNCCN 17th Annual Conference: Clinical Practice Guidelines & Quality Cancer CareOncLiveUnder salvage therapy, cyclophosphamide VAD (vincristine/doxorubicin/ dexamethasone), dexamethasone, lenalidomide, and thalidomide are no longer recommended, while bortezomib treatment is added as a combination treatment with DT-PACE (dexamethasone, .
Diffuse Large B-Cell Lymphoma: Current Treatment Approaches - Cancer Network
Diffuse Large B-Cell Lymphoma: Current Treatment ApproachesCancer NetworkWhile a series of trials support R-CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone, plus rituximab)-21 as the standard of care for all patients, DLBCL has substantial biological and clinical heterogeneity, leading to marked differences .
Docs Need Primer on Long-Term Effects of Chemotherapy - Family Practice News Digital Network
Family Practice News Digital NetworkDocs Need Primer on Long-Term Effects of ChemotherapyFamily Practice News Digital NetworkOnly 6% of primary care physicians were able to identify the main long-term effects (LEs) of doxorubicin (Adriamycin), paclitaxel (Taxol), oxaliplatin (Eloxatin), and cyclophosphamide (Cytoxan), compared with 65% of oncologists surveyed.